Spinal muscular atrophy type 1: management and outcomes
Related Experiment Video
Updated: Aug 9, 2026
Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
Published on: October 3, 2011
John R Bach1, J Scott Baird, Daniel Plosky
1Department of Physical Medicine and Rehabilitation, UMDNJ-New Jersey Medical School, Newark, New Jersey 07103, USA. bachjr@umdnj.edu
Insights
Spinal muscular atrophy type 1 (SMA1) patients benefit from respiratory support. Noninvasive ventilation offers better long-term outcomes, including speech and fewer hospitalizations, compared to tracheostomy.
Area of Science:
- Pediatric Neurology
- Pulmonology
- Genetics
Background:
- Spinal muscular atrophy type 1 (SMA1) is a severe genetic neuromuscular disorder characterized by progressive muscle weakness and respiratory failure.
- Respiratory support is crucial for survival in SMA1 patients, with options including tracheostomy ventilation and noninvasive ventilation.
- Understanding the long-term outcomes of different ventilation strategies is essential for optimizing patient care.
Purpose of the Study:
- To compare survival, hospitalization rates, speech capabilities, and overall outcomes in SMA1 patients receiving noninvasive ventilation versus tracheostomy.
- To evaluate the impact of respiratory support methods on the quality of life and functional abilities of children with SMA1.
Main Methods:
- Retrospective analysis of 56 SMA1 patients who developed respiratory failure before age 2.
- Patients were divided into two groups: Group A (tracheostomy ventilation) and Group B (noninvasive ventilation with assisted coughing).
- Data collected included age at intervention, survival duration, hospitalization frequency, and communication abilities.
Main Results:
- Tracheostomy (Group A) was associated with fewer hospitalizations until age 3 but more after age 5 compared to noninvasive ventilation (Group B).
- Most tracheostomy patients (15/16) lost spontaneous breathing and speech ability, whereas noninvasive ventilation allowed for speech in most patients.
- Noninvasive ventilation patients experienced longer survival and better functional outcomes, with 3 requiring continuous high-level support and 4 unable to communicate verbally.
Conclusions:
- SMA1 children can achieve long-term survival with either tracheostomy or noninvasive respiratory support.
- Noninvasive ventilation is linked to reduced hospitalizations after age 5, freedom from daytime ventilator dependence, and preserved speech.
- Noninvasive ventilation appears to be a superior strategy for improving functional outcomes and quality of life in SMA1 patients.
Abstract:
Our objectives were to describe survival, hospitalization, speech, and outcomes related to respirator needs for spinal muscular atrophy type 1 (SMA1) patients, using noninvasive or tracheostomy ventilation. From 65 SMA patients referred to our clinic since 1996, we chose 56 SMA1 patients who developed respiratory failure before age 2 years. Patients either had tracheostomy tubes (group A), or used noninvasive ventilation and assisted coughing; a previously reported extubation protocol (group B) was used as needed. Sixteen patients underwent tracheostomy at 10.8 +/- 5.0 months of age, 33 were in group B, and 7 others died without life-support interventions. Compared to group B, group A patients had fewer hospitalizations until age 3 years, but more after age 5, and 15 of 16 lost all spontaneous breathing tolerance posttracheostomy and could not speak. One group A patient died at 16 months of age, and the others were 73.8 +/- 57 months of age (the oldest was 19 years old). Two group B patients died at 6 and 13 months, respectively, whereas the other 31 were 41.8 +/- 26.0 months (and up to 8.3 years) old. Three of 31 in group B required high-span positive inspiratory pressure plus positive end-expiratory pressure (PIP + PEEP) continuously with minimal tolerance for breathing on their own, and 4 could not communicate verbally.In conclusion, SMA type 1 children can survive beyond 2 years of age when offered tracheostomy or noninvasive respiratory support. The latter is associated with fewer hospitalizations after age 5 years, freedom from daytime ventilator use, and the ability to speak.
More Related Videos
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
12:35Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
Published on: March 17, 2012
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:15Parkinson's Disease: Overview
01:11Alterations in Muscle Tone lll